We normally talk about the characteristics we love to find in stocks. But this week, we bring you all the things we hate. We’ve all gotten caught in a hype cycle or seen an investment thesis degrade, so having a list of red flags to look for is a great way to check in with your portfolio.

They include:

Over-promising. It can be hard to spot fraud in the early days, but if a company is hyperbolic in its language, give it some time. Pre-revenue companies are especially prone to talking big, and they’re a hard pass for Mike.

Management woes. Referencing Good to Great by Jim Collins, Emmet reminds us a great CEO is someone with fierce resolve and a degree of humility. The inverse can be very damaging and often looks like prioritizing short-term gains and selling significant stock during all-time highs. A revolving door of CEOs is also a huge red flag.

Creative accounting. If you see a big difference between net profit and cash flows, or an overuse of adjusted EBITDA, you might want to think twice. These can indicate profits are tied up in unpaid bills or outsized stock-based compensation, which dilutes investors over time.

Deteriorating fundamentals. Slowing revenue growth, compressed margins, bland return on equity (ROE), or rising customer acquisition costs can all signal a business entering decline. However, if you think you’ve spotted a potential turnaround play, these may also be present.

Unforeseen circumstances. Significant, world-changing disruption is also hard to predict, which is why diversification is key. SaaS businesses being upended by AI is a good example.

Valuation. You can buy great businesses, but at extreme prices they can be bad investments. Don’t completely avoid stocks at 25x earnings, as a company can keep delivering, but stay within the realms of reality.

Customer concentration. Reliance on a single client can be a huge risk. It’s particularly prevalent among small businesses that serve enterprises. Progyny (PGNY) vs Amazon (AMZN) is a good case study.

High dividend yield. Yields of 8–10% are often too high. If the payout ratio is above 100%, the company may be borrowing money to pay investors. That won’t last long.

Binary outcomes. For example, pharmaceutical companies waiting for regulatory approval. If they fail, the business can collapse.

After all that, Emmet brings us Follow Prophet, talking about its recent addition, SPX Technologies (SPXC).

Finally, we celebrate Ireland’s new investing accounts. Simon Harris has announced that we will follow the Swedish model, with a launch expected in 2027. We’ll break down the full announcement next week.

Our Horizon portfolio is a boutique service led by our co-founder and lead investor, Emmet Savage. According to 100-bagger expert Chris Mayer, “no one owns more 100-baggers than Emmet”.

This week, he’s adding a new stock that has passed 3 AI screeners and got a shout out from Porter Stansbury. Lucky for Stock Club listeners, they can claim as exclusive offer by emailing: frank@mywallst.com.

Psssst…. We don’t think you’ll want to miss this year’s Investicon. Grab your early bird tickets now: https://www.investicon.ie/

Become a successful investor by checking out all the content MyWallSt has to offer:

📩 Email us: pod@mywallst.com

📚 Learn the fundamentals of investing by downloading our free Learn app: https://bit.ly/3DXPOz7

💻 Keep updated on stock market news by visiting our blog: https://mywallst.com/blog/

🎧 Tune in to our podcast Stock Club to stay updated on weekly news: https://mywallst.com/stock-investment-podcast/

🎉 Follow MyWallSt on social:

❌ X: @MyWallStHQ

💃 TikTok: @MyWallSt

📸 Instagram: @MyWallSt

🖥️ Facebook: @MyWallSt

👔 LinkedIn: MyWallSt

(adjust these after intro)

00:00 Intro04:31 Shorting Stocks Talk10:35 Founder CEOs vs Insider Selling17:35 Creative Accounting22:35 Deteriorating Fundamentals30:59 Valuation Reality Check32:27 Customer Concentration34:20 High Dividend Yield37:25 Following Prophet43:24 Ireland’s New Investment Scheme

Investor Down Under — g’day. We’ve long loved hunting for underappreciated stocks abroad, and over the years we’ve realized Australia is a particularly great place to find them. With its investing culture on the rise, this week we’re highlighting some of our local favorites.

Emmet brings you a “high-quality moonshot with revenue.” Out of character for him, it’s Telix Pharmaceuticals (ASX: TLX). He normally avoids pharma and fashion, mostly because it rhymes. Telix develops and sells radiopharmaceuticals, including diagnostic tools (“theranostics”), primarily in oncology.

Its annualized revenue growth is a thing of beauty. It went from generating $4 million in revenue in 2020 to $800 million in 2025. That growth is driven entirely by its diagnostic technology, not treatment, which is still in development. This makes it a potentially less risky cancer-curing play.

If you’re a fan of Aussie stocks and want to hear Mike’s all-time favorite, you’ll need a Nexus 3 subscription. But his second favorite is Supply Network Limited (SNL), a provider of bus and truck parts. It’s a classic Mike, and Peter Lynch, type of play.

Its moat lies in its depth of inventory and expertise in parts interpreting. It also has strong local market knowledge. Trucking is huge in Australia, but fleets are aging and often consist of vehicles from dozens of manufacturers, many concentrated in different parts of the country. Knowing what parts will be needed and where is a major advantage. The company has also grown revenue at a 17% CAGR over the past decade.

Modernization could pose a threat through automation or electrification, but it’s unlikely to play out meaningfully over the next decade.

We wrap up with Mike and Emmet sharing how they would invest $10K across these stocks.

If you’re a new investor looking to start off on the right foot, we think Stock of the Month is the service for you. Every month, we pitch you one accessible, long-term stock we love, with a comprehensive write-up. We’ve been lucky to have some big winners, like Shopify which has returned more than 2600% since we picked it in 2017.

Head to https://www.mywallst.com/stock-of-the-month to get all the details.

Psssst…. We don’t think you’ll want to miss this year’s Investicon. Grab your early bird tickets now: https://www.investicon.ie/

Become a successful investor by checking out all the content MyWallSt has to offer:

📩 Email us: pod@mywallst.com

📚 Learn the fundamentals of investing by downloading our free Learn app: https://bit.ly/3DXPOz7

💻 Keep updated on stock market news by visiting our blog: https://mywallst.com/blog/

🎧 Tune in to our podcast Stock Club to stay updated on weekly news: https://mywallst.com/stock-investment-podcast/

🎉 Follow MyWallSt on social:

❌ X: @MyWallStHQ

💃 TikTok: @MyWallSt

📸 Instagram: @MyWallSt

🖥️ Facebook: @MyWallSt

👔 LinkedIn: MyWallSt

00:00 Intro01:40 Kalashi and predictive markets rant

06:41 Why Focus on Australia14:39 Telex Pharmaceuticals 18:32 Why Telex Excites Investors20:44 Moat and Market Expansion21:52 Risks26:30 Supply Network Limited (ASX: SNL)28:40 Moat Through Parts Expertise and Market Outlook37:57 10K Split and Wrap Up

This week, Emmet and Mike are digging into one of the hottest trends of our futuristic world: human longevity. We’ve all seen Bryan Johnson on our social feeds, but the business of living longer is more than just a meme. Today, new-age pharmaceutical companies are leveraging AI to reinvent the drug development process—making it faster, cheaper, and more customizable. If they’re successful, it could become one of the most important scientific innovations of all time.

This raises the question: how do you invest in it?

Emmet sees four categories:

• Metabolic longevity — Eli Lilly, Novo Nordisk
• Early disease detection — Guardant Health, Exact Sciences
• Longevity infrastructure — Thermo Fisher, Danaher Corp
• Moonshots — Recursion Pharmaceuticals Inc

But which stocks are the lads’ favorites?

Mike favors Tempus AI (TEM) for its two-pronged business model, composed of diagnostics and data. The diagnostics side is similar to Guardant Health, focusing on hereditary and sequencing tests. The data side consists of vast libraries of medical data that are licensed to other pharma and biotech companies, enabling things like trial design, pre-validation, and patient enrollment. They also have some impressive stats: net revenue retention sits at 126%, and they have over a billion dollars in backlog.

Emmet goes with a stock he previously added to his watchlist, but later removed due to its complexity: Recursion Pharmaceuticals. It has a validated, full-stack platform for AI-driven drug discovery, but currently licenses data from Tempus AI. It recently achieved its first patented result from its AI system, which is considered a major breakthrough.

They wrap up by sharing which stock they would invest in today.

In celebration of St. Patrick’s Day, all of our services are on sale. From Horizon to Prophet, it’s a great time to find your next life-changing investment (at a discount). Importantly, our Insider Bot lives inside Horizon so if you want to invest like a CEO or CFO now is the time.

To lock in your special rate, email frank@mywallst.com

Psssst…. We don’t think you’ll want to miss this year’s Investicon. Grab your early bird tickets now: https://www.investicon.ie/

Become a successful investor by checking out all the content MyWallSt has to offer:

📩 Email us: pod@mywallst.com

📚 Learn the fundamentals of investing by downloading our free Learn app: https://bit.ly/3DXPOz7

💻 Keep updated on stock market news by visiting our blog: https://mywallst.com/blog/

🎧 Tune in to our podcast Stock Club to stay updated on weekly news: https://mywallst.com/stock-investment-podcast/

🎉 Follow MyWallSt on social:

❌ X: @MyWallStHQ

💃 TikTok: @MyWallSt

📸 Instagram: @MyWallSt

🖥️ Facebook: @MyWallSt

👔 LinkedIn: MyWallSt

00:00 Intro01:31 Why Longevity Matters07:31 Demis Hassabis on the Future of AI15:08 Longevity Investing Archetypes24:16 Tempus AI Overview31:39 Recursion Pharma Pitch45:07 10K Portfolio Split